Alvotech
ALVO$1.29B
Small CapNASDAQBiotechnology🇺🇸North America1.0K employees
Drugs in Pipeline
6
Phase 3 Programs
6
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
ALVO News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Adalimumab
Plaque Psoriasis
AVT05 (proposed biosimilar to golimumab)
Rheumatoid Arthritis
AVT03
Osteoporosis, Postmenopausal
Stelara
Psoriasis
Adalimumab originator
Plaque Psoriasis
AVT06 (proposed aflibercept biosimilar)
Neovascular (Wet) AMD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Adalimumab | Phase 3 | Plaque Psoriasis | - | - |
AVT05 (proposed biosimilar to golimumab) | Phase 3 | Rheumatoid Arthritis | - | - |
AVT03 | Phase 3 | Osteoporosis, Postmenopausal | - | - |
Stelara | Phase 3 | Psoriasis | - | - |
Adalimumab originator | Phase 3 | Plaque Psoriasis | - | - |
AVT06 (proposed aflibercept biosimilar) | Phase 3 | Neovascular (Wet) AMD | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply